gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Article

Send article

Posterior vitreous detachment following intravitreal drug injection

Meeting Abstract

Search Medline for

  • Johann-Ulrich Geck - Universitäts-Augenklinik Göttingen
  • N. Pustolla - Universitäts-Augenklinik Göttingen
  • H. Baraki - Universitäts-Augenklinik Göttingen
  • H. Hoerauf - Universitäts-Augenklinik Göttingen

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg38

doi: 10.3205/11rg38, urn:nbn:de:0183-11rg380

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2011/11rg38.shtml

Published: June 15, 2011

© 2011 Geck et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Objective: To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injection of different intravitreal drugs.

Methods: This prospective observational trial includes 61 patients (61 eyes) with different underlying ocular diseases (n=47: exsudative age related macular degeneration, n=8: cystoid macular edema (CME) after retinal vein occlusion and n=6: CME of other origin). Bevazicumab (1.25 mg) was injected in 25 eyes, Ranibizumab (0.5 mg) in 27 eyes, Triamcinolone (4 mg) in 6 eyes and a combination of Bevazicumab and Triamcinolone in 3 eyes. Patients with initial PVD determined were excluded. If the vitreous was still attached, patients were followed at least 4–6 weeks after their last injection by Fourier-Domain OCT, biomicroscopy and ultrasound B examination. Mean follow-up period was 11.1 weeks.

Results: Overall 15 of 61 eyes developed a PVD after intravitreal injection (n=6 after Ranibizumab, n=7 after Bevacizumab and n=2 after Triamcinolon). PVD occurred in n=3 eyes after the first injection, in n=3 after the second injection and in n= 7 eyes after the third injection.

Conclusions: Intravitreal injection of commonly used drugs seems to induce posterior vitreous detachment and may thereby influencing the outcome of the underlying disease.